Fosdagrocorat

Fosdagrocorat (also known as PF-04171327) is a glucocorticoid prodrug that was under development by Pfizer for the treatment of rheumatoid arthritis. It is a selective glucocorticoid receptor modulator (SGRM) that was designed to provide the anti-inflammatory benefits of glucocorticoids without the associated side effects.

Chemistry

Fosdagrocorat is a prodrug of dagrocorat, a non-steroidal glucocorticoid receptor agonist. The prodrug is converted to the active drug in the body by the action of esterase enzymes. The chemical structure of fosdagrocorat includes a phosphonate group, which is responsible for its prodrug properties.

Pharmacology

The pharmacological action of fosdagrocorat is based on its conversion to dagrocorat, which binds to the glucocorticoid receptor and modulates its activity. This results in a reduction of inflammation and immune response, which are key factors in the pathogenesis of rheumatoid arthritis.

Clinical trials

Fosdagrocorat was evaluated in several clinical trials for the treatment of rheumatoid arthritis. The results showed that the drug was effective in reducing the symptoms of the disease, but its development was discontinued due to concerns about its safety profile.

See also

• List of investigational drugs
• Glucocorticoid receptor
• Rheumatoid arthritis

References

‎